Granted Patent B2

US 12,318,139 · App. 17/889,859 · Granted Jun 3, 2025

Inventors: W. David Lee (Brookline, MA); Jorge Ferrer (West Newton, MA)

Assignee: Lumicell, Inc.

A61B18/24A61B18/02A61B18/12A61B18/20A61B18/22A61B34/20A61B90/39A61B2017/00057A61B2017/0011A61B2018/00029A61B2018/00351A61B2018/00434A61B2018/00565A61B2018/00577A61B2018/00642A61B2018/00886A61B2018/00904A61B2018/00982A61B18/14A61B2018/20351A61B2018/20359A61B2018/20361A61B2018/2283A61B90/30A61B90/361A61B2503/40A61B2562/028A61B2576/00

Abstract

Claims (34)

1. An in vivo method of treating a subject comprising:

(a) administering a composition comprising a molecular imaging probe to the subject, wherein the molecular imaging probe labels diseased cells;

(b) permitting the molecular imaging probe to clear preferentially from healthy tissue leaving the diseased cells labeled;

(c) performing initial resection surgery to remove diseased cells from the subject thereby creating a resection bed;

(d) directing light towards the resection bed to excite the molecular imaging probe;

(e) obtaining an in situ fluorescence image of the resection bed using an imaging system; and

(f) detecting the labeled diseased cells, if present in the resection bed, using the in situ fluorescence image.

2. The method of claim 1 , wherein the molecular imaging probe is a clearance differential probe including a fluorescent label attached to a pharmacokinetic modifier that results in the molecular imaging probe clearing preferentially from the healthy tissue leaving the diseased cells labeled.

3. The method of claim 2 , wherein the fluorescent label has optical properties in the visible spectrum of 350 nm to 670 nm.

4. The method of claim 2 , wherein the pharmacokinetic modifier has a molecular weight of between 20,000 g/mol and 40,000 g/mol.

5. The method of claim 2 , wherein the pharmacokinetic modifier is selected from the group consisting of polyethylene glycol (PEG), dextran, polyethylene oxide (PEO), polyoxyethylene (POE), methoxypolyethylene glycol (MPEG), methoxypolypropylene glycol, polyethylene glycol-diacid, polyethylene glycol monoamine, MPEG monoamine, MPEG hydrazide, MPEG imidazole, copolymers of polyethylene glycol and monoxypolypropylene glycol, branched polypropylene glycol, polypropylene glycol, and polylacic-polyglycolic acid.

6. The method of claim 2 , wherein the molecular imaging probe comprises a polyethylene glycol (PEG) having a molecular weight of between 20,000 g/mol and 40,000 g/mol.

7. The method of claim 2 , wherein the fluorescent label is selected from the group consisting of Cy3, Cy3.5, Cy5, Alexa 568, Alexa 546, Alexa 610, Alexa 647, ROX, TAMRA, Bodipy 576, Bodipy 581, Bodipy TR, Bodipy 630, VivoTag 645, and Texas Red.

8. The method of claim 2 , wherein the pharmacokinetic modifier comprises polyethylene glycol (PEG) or methoxypolyethylene glycol (MPEG).

9. The method of claim 2 , wherein the fluorescent label is Cy5.

10. The method of claim 1 , wherein the composition is administered systemically to the subject.

11. The method of claim 1 , wherein the composition is applied to a tissue surface of the subject.

12. The method of claim 1 , wherein the molecular imaging probe is imaged at between 12 and 36 hours after administration.

13. The method of claim 1 , wherein the in situ fluorescence image allows for selective detection of the labeled diseased cells within about 1 cm from a surface of the resection bed and excludes deep tissue emission.

14. The method of claim 1 , wherein the imaging system comprises:

(a) a light source that directs the light towards the resection bed;

(b) an optical receptor configured to receive light from the resection bed and obtain the in situ fluorescence image; and

(c) an image processor that receives the in situ fluorescence image from the optical receptor and detects the labeled diseased cells if present in the resection bed.

15. The method of claim 14 , wherein the optical receptor comprises an array of pixels with an analysis resolution equal to a diameter of the diseased cells.

16. The method of claim 14 , wherein the imaging system locates the labeled diseased cells within a field of view of the optical receptor.

17. The method of claim 16 , wherein the image processor outputs camera pixel locations of the labeled diseased cells.

18. The method of claim 14 , wherein the image processor detects the diseased cells, if present in the resection bed, by comparing a fluorescence at each location in the image with a fluorescence threshold.

19. The method of claim 1 , further comprising: performing further resection surgery to remove the labeled diseased cells if the labeled diseased cells are detected in (f).

20. The method of claim 1 , wherein the molecular imaging probe is an activatable probe comprising an enzyme activation site.

21. The method of claim 20 , wherein the molecular imaging probe comprises a fluorescent label and a quencher.

22. The method of claim 21 , wherein the quencher quenches a fluorescence emission of the fluorescent label until cleavage of the enzyme activation site.

23. The method of claim 21 , wherein the quencher is a QSY quencher, a dabcyl quencher, an Iowa black quencher, or a Black Hole quencher.

24. The method of claim 23 , wherein the quencher is QSY21.

25. The method of claim 20 , wherein the enzyme activation site is cleaved by cathepsin.

Assignments (2)

Continuity (8)

References Cited (217)